Cronos achieved record Q4 2025 net revenue of 44531000, up 47% year-over-year, driven by higher cannabis flower sales in Israel and other countries and stronger Canadian extract sales. Gross profit increased 50% to 16189000, and Adjusted EBITDA turned positive at 456000. The company reported a net loss of 491000 in the quarter.

Cronos Group reported a 27% increase in net revenue for Q4 2024, reaching $30.3 million, driven by strong performance in the Canadian and Israeli markets. The company's strategic investments and brand leadership have positioned it for continued growth in the global cannabis industry.

Cronos Group reported a 38% increase in net revenue for Q3 2024, reaching $34.3 million. The company's Spinach® brand became the top-selling cannabis brand in Canada, and Cronos maintains a strong balance sheet with $862 million in cash and cash equivalents. The consolidation of Cronos Growing Company has strengthened the supply chain, which is anticipated to lead to improved margins.

Cronos Group reported a strong second quarter in 2024, achieving record net revenue of $27.8 million, a 46% increase year-over-year. This growth was driven by strong performance in Canada, Israel, Germany and the UK. The company is focused on quality and innovation, maintaining a strong balance sheet.

Cronos Group reported a 30% year-over-year increase in net revenue, reaching $25.3 million in Q1 2024. This growth was primarily driven by strong performances in Canada and Israel. The company maintains a strong balance sheet with $855 million in cash and cash equivalents.

Cronos Group reported a 9% increase in consolidated net revenue for Q4 2023 compared to Q4 2022. The company improved cash flow from operations and expanded its product portfolio in Canada and Israel. They ended the year with approximately $862 million in cash and short-term investments.

Cronos Group reported a 22% increase in net revenue to $24.8 million for Q3 2023, driven by growth in the Canadian market. The company also achieved cost reductions and improved gross margin. However, the positive results were overshadowed by the events in Israel, Cronos' second largest operating market.

Cronos Group reported a decrease in net revenue compared to Q2 2022, primarily due to lower cannabis flower sales in Israel and an adverse price/mix in Canada. However, the company improved its net income and adjusted EBITDA through cost reduction efforts and improved balance sheet management. They are discontinuing net revenue guidance due to market turbulence.

Cronos Group's Q1 2023 net revenue decreased by $4.9 million compared to Q1 2022, primarily due to lower cannabis flower sales in the Rest of World segment and a decline in the U.S. segment. However, the company is on track to achieve the high end of its projected $10 to $20 million in cash operating expense savings for 2023 and is targeting positive cash flow in 2024.

Cronos Group's Q4 2022 net revenue decreased by $2.9 million compared to Q4 2021, primarily due to lower cannabis flower sales in Canada and the U.S. Gross profit declined by $2.2 million, while adjusted EBITDA improved by $6.1 million due to cost-saving initiatives.

Cronos Group's Q3 2022 results showed a mixed performance. Consolidated net revenue increased by 3% year-over-year to $20.9 million, with significant growth in the Israeli market offsetting declines in the U.S. The company is on track to achieve $20 to $25 million in operating expense savings for 2022.

Cronos Group reported a 48% year-over-year increase in consolidated net revenue, reaching $23.1 million in Q2 2022. The company is undergoing a strategic realignment to focus on key brands and improve operational efficiency.

Cronos Group reported a 99% year-over-year increase in net revenue to $25.0 million in Q1 2022, driven primarily by growth in the Israeli medical market and the Canadian adult-use market. The company's gross profit improved significantly, and it initiated a strategic realignment to optimize operations and drive sustainable growth.

Cronos Group's Q4 2021 net revenue increased by $8.7 million compared to Q4 2020, driven by growth in the adult-use market in Canada and increased sales in the Israeli medical market. Gross profit improved by $16.8 million, and adjusted EBITDA improved by $25.8 million year-over-year.

Cronos Group's Q3 2021 saw a significant increase in consolidated net revenue, driven by growth in the adult-use market in Canada, increased sales in the Israeli medical cannabis market, and increased sales in the U.S. segment. The company is realigning its business to focus on brands, centralizing functions, and prioritizing investments in innovation.

Cronos Group's Q2 2021 net revenue increased by $5.7 million year-over-year, driven by growth in the Canadian adult-use cannabis market and increased sales in the Israeli medical cannabis market. The company also made a strategic investment in PharmaCann, a leading U.S. cannabis company.

Cronos Group's Q1 2021 net revenue increased by 50% year-over-year to $12.6 million, driven by growth in the Canadian adult-use market, Israeli medical cannabis market, and U.S. hemp-derived CBD products. The gross loss decreased by $3.5 million from Q1 2020. Adjusted EBITDA loss increased marginally to $37.1 million.

Cronos Group's Q4 2020 net revenue increased by $9.7 million compared to Q4 2019, primarily driven by growth in the adult-use market in Canada, sales in the Israeli medical market, and growth in the U.S. segment. The company's gross loss decreased by $5.2 million year-over-year, while the adjusted EBITDA loss increased by $1.5 million.

Cronos Group reported a net revenue of $11.4 million, a gross loss of $1.5 million, and an operating loss of $41.2 million for Q3 2020. The company saw revenue growth primarily driven by the Canadian cannabis market, the Redwood acquisition, and the Israeli medical cannabis market.

Cronos Group reported a net revenue increase of $2.2 million compared to Q2 2019, driven by growth in the Canadian adult-use market and the inclusion of the Redwood acquisition. However, the company experienced a decrease in gross profit due to increased cost of sales and an inventory write-down.

Cronos Group focused on core strategic initiatives to drive long-term growth. They moved closer to entering the Israeli medical cannabis market and continued to launch innovative products, adapting to an online-first distribution model. Despite COVID-19 challenges, the company remains agile and focused, progressing with product innovation and R&D projects.

Cronos Group's Q4 2019 net revenue increased by $3.0 million compared to Q4 2018, primarily driven by increased product volume in the Rest of World segment and the Redwood acquisition. However, the company experienced a significant decrease in gross profit due to a $24.0 million inventory write-down, and the operating loss increased due to the write-down and increased operating expenses.